pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›YUSIMRY
drug · antibody
save

YUSIMRY

Marketedupdated 6mo ago
by $COGT Cogent Biosciences, Inc.🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval182 co-mentions · 86 sources
  • drugHUMIRA172 co-mentions · 86 sources
  • drugadalimumab152 co-mentions · 86 sources
  • drugAMJEVITA81 co-mentions · 81 sources
  • drugABRILADA81 co-mentions · 81 sources
  • company$ABBVAbbVie Inc.61 co-mentions · 61 sources
  • drugCYLTEZO24 co-mentions · 12 sources
  • drugIDACIO16 co-mentions · 8 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.

targets

Tumor necrosis factor

all catalysts(5)

approval · 5
Dec 17, 2021
approval
$COGT31.64+6.98%
5y ago
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
Feb 27, 2023
approval
$COGT31.64+6.98%
4y ago
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
Mar 31, 2023
approval
$COGT31.64+6.98%
4y ago
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
Sep 13, 2023
approval
$COGT31.64+6.98%
3y ago
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→
Nov 10, 2025
approval
$COGT31.64+6.98%
1y ago
YUSIMRY (ADALIMUMAB-AQVH) — FDA approval
YUSIMRY
→

News(10)

  • Deaths, failed trials and other recent setbacks in the autoimmune space
    Novartis, Bristol Myers Squibb, argenx and more have recently been hit with challenges as they attempt to advance assets targeting autoimmune diseases, with some programs being axed entirely while…
    biospace · 1d ago
  • AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
    AbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase 1 inflammatory bowel disease candidate.
    fiercebiotech · 13d ago
  • AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals
    Strong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.
    biospace · 17d ago
  • 5 new drug launches that defied industry expectations
    A clearly superior clinical profile, reasonable pricing and easy access has helped a handful of recently approved therapies achieve impressive launches.
    biospace · 20d ago
  • AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations
    AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed some analysts, raising q…
    biospace · 25d ago
  • Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
    Brepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug hit all primary and secondary endpoints in a pair of Phase 3 non-infect…
    biospace · 26d ago
  • Celltrion picks up another Kaigene autoimmune antibody for up to $580.5M
    Celltrion has licensed a preclinical antibody targeting autoimmune conditions from Maryland-based biotech Kaigene in a deal worth up to $580.5 million, marking another step in the South Korean drug…
    fiercebiotech · 26d ago
  • Roivant, continuing ascent, claims another victory for rare disease drug
    Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also be a “best-in-disease” medicine for an inflammatory eye condition, one an…
    biopharma_dive · 26d ago
  • STAT+: Roivant says closely watched immune drug succeeded in new eye disease
    An immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease non-infectious uveitis.
    stat · 27d ago
  • As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
    AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster ca…
    biospace · 28d ago
view all news mentions →
brand
YUSIMRY
trade names
Amgevita, Amsparity, Cyltezo, Halimatoz, Hefiya, Hulio
generic
ADALIMUMAB-AQVH
MOA
12.1 Mechanism of Action Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques. In Ps, treatment with YUSIMRY may reduce the epidermal thickness and infiltration of inflammatory cells. The relationship between these pharmacodynamic activities and the mechanism(s) by which adalimumab products exert their clinical effects is unknown. Adalimumab products also modulate biological responses that are induced or regulated by TNF, including changes in the concentrations of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC 50 of 1-2 X 10 -10 M).
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?